Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline

Authors: Peres, E.¹; Khaled, Y.¹; Krijanovski, O.I.¹; Mineishi, S.¹; Levine, J.E.¹; Kaul, D.R.²; Riddell, J.²

Source: Transplant Infectious Disease, Volume 11, Number 1, February 2009 , pp. 57-63(7)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

E. Peres, Y. Khaled, O.I. Krijanovski, S. Mineishi, J.E. Levine, D.R. Kaul, J. Riddell IV. Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline.

We present a case of progressive Mycobacterium chelonae ssp. chelonae necrotizing pneumonia after hematopoietic stem cell transplantation (HSCT) in the presence of chronic graft-versus-host disease. The patient failed to respond to standard combination therapy with multiple agents and developed resistance to most drugs over the course of treatment. Tigecycline, a new glycylcycline antimicrobial agent with in vitro activity against M. chelonae, was then used with a clinical response to treatment. To our knowledge, this is the first reported case demonstrating tigecycline to have a degree of clinical effectiveness to treat refractory pulmonary infection with M. chelonae in an HSCT recipient.

Keywords: stem cell transplant; non-tuberculous mycobacterium; pneumonia; tigecycline; Mycobacterium chelonae

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1399-3062.2008.00351.x

Affiliations: 1: Blood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA, and 2: Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

Publication date: 2009-02-01